Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$JAGX can explode at any time - next stop is 50 cents then a dollar.
imho
💥💥💥💥💥💥💥💥💥💥💥💥🤑🤑🤑🤑🤑🤑🤑🫶🫶🫶🫶🫶🫶🫶🫶🚀🚀🚀🚀🚀🚀🚀🚀
We are about to clear the tower 🚀
JAGX
$JAGX has been rising and rising for days and we have to follow the trend and those who follow the trend are the winners and where does it want to go now?
$JAGX wants to go to dollar land - LOL
BOOOOOOOOOOOOOOOOOOM $JAGX IS READY TO EXPLODE EVERY DAY A LITTLE UP AND ONE DAY EXPLOSION
all only imho
About to explode here 🚀 JAGX
JAGX what's going on here!! 😃
the sellers seem to be out big.... going up for the 6rd day in a row and follow the trend and you will be on the winning side , IMHO
$JAGX IS READY FOR DOLLARLAND
🔥🔥🔥🔥🚀🚀🚀🔥🚀
The trend is our friend ➡️↗️
JAGX
Absolute strength today especially now $JAGX seems to be taking off
then after .50 Dollarland
imho
pre again up // day by day now higher and higher 🤑🤑🤑🤑🤑
GREAT INFOS - SHOULD BOOMING
JAGX is a great $$$$$ opportunity.
Summary of today:
1) NASDAQ in RED , we finished +3% after a +15% day, which seems GOOD
2) 3 million short shares returned / covered
3) Large scale orders (buy side)
i hope soon .30 - .50 -$1
Not yet. New hod 25.3 today is a strong indicator that stock continues to move higher.
maybe a/h again BOOOOOOM ?
PLEASE READ IF YOU ARE NEW HERE:
I think you will be pleasantly surprised at your own due diligence. Below are the current indications being studied:
https://jaguar.health/pipeline/
If Crofelemer receives FDA approval for (CTD), this will open up opportunities for their other indications to be funded and studied.
Just think for a moment, how expensive a GLOBAL trial is to get a drug to market. $100's of millions of dollars, you have to have manufacturing/ test locations setup in multiple countries.
Lisa has done the leg work and has the infrastructure in place. Along with the Partnership with GEN in Turkey, they are preparing for the big leagues.
happy trading day...
selling jagx,buying muln.
Knock knock knocking on .25’s door
Look at the large scale orders at Webull... you will be surprised what allready happened
.30 today would be nice
We break that .26 resistance today :)
JAGX
Looks like we can see spike towards .50
Good morning RammageRaul and other JAGX-ers!
Nice premarket spike today.
$JAGX
3m shares returned already lets eat boys .25+ today
9M PREMARKET VOL AND RISING, HOLD FOR GOLD GENTS
Currently no walls on this thing, it's trading freely with market now. Shall fly past $6 with it's real valuations
Volume looking good, next stop .30c
TICK TOCK where are the cry baby shorts now.... oh wait. probably buying
OH YEAH ❤️❤️ THEN BOOOOOOOOOM ❤️❤️
Wow traders chew .25 candies now....
$JAGX 😍 is getting ready to fly - will it hit 50 cents today and the dollar this week? 🔥🔥🔥🔥🔥
+ 1 million volume, and price allready up by 8%. Seems like a very promising day?
No buyout. But partnerships
FOMO yet to come !
If we now rise day by day, then euphoria will arise and we will see the dollar rise faster than many people think.
Followers
|
150
|
Posters
|
|
Posts (Today)
|
9
|
Posts (Total)
|
6090
|
Created
|
12/01/15
|
Type
|
Free
|
Moderators ProfitChaser oldstocks DTGoody powerbattles SmellMyFinger |
Jaguar Health, Inc. $JAGX
Bringing Plant-based Medicines to Life™
Pharmaceutical Manufacturing
San Francisco, California
Jaguar Health’s organizational framework is designed to enable our product pipeline to reach the world’s interconnected marketplace, allowing for development and commercialization opportunities worldwide.
Products:
Mytesi Crofelemer 125mg delayed release tablets
Mytesi is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy
Market size of the FDA HIV Mytesi Crofelemer could be $25-$30 Million in the USA
Mytesi has a novel mechanism of action that modulates chloride secretion in the gastrointestinal tract, reducing excessive chloride and accompanying water flow and relieving watery diarrhea.
Mytesi is not indicated for the treatment of infectious diarrhea. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (6%), bronchitis (4%), cough (4%), flatulence (3%), and increased bilirubin (3%).
Canalevia-CA1 Crofelemer delayed release tablets
Distributors listed:
https://www.canalevia.com/distributor-information
CANALEVIA-CA1 is conditionally approved for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.
Lytham Partners Investor Select Conference February 1st, 2024
https://wsw.com/webcast/lytham10/jagx/2084640
Pipeline: https://jaguar.health/pipeline/
How to calculate the value of drugs and biotech companies
https://www.baybridgebio.com/drug_valuation.html
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study , a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative is focused on developing novel prescription medicines derived from plants for mental health indications.
A Case Report: Improved Control of Tyrosine Kinase Inhibitor-Induced Diarrhea
Despite the efficacy of tyrosine kinase inhibitors (TKIs) across multiple cancers, side effects including treatment-related diarrhea can impede a patient’s ability to reach therapeutic doses or stay on therapy.
Below, we present the case of a 72-year-old patient with metastatic papillary renal cell carcinoma recurrent despite nephrectomy.
Over the course of treatment, the patient received multiple different tyrosine kinase inhibitors with varying efficacy.
Treatment with the TKI cabozantinib after failure of two prior TKIs resulted in a clinical response with shrinkage of his nodal metastatic disease.
However, the severe treatment-related diarrhea refractory to conventional management required both dose holds and dose reductions of cabozantinib.
Off-label administration of crofelemer, a novel FDA-approved antidiarrheal agent, successfully controlled the treatment-related diarrhea and allowed resumption and partial dose increase of cabozantinib.
This case suggests that crofelemer could be a viable therapeutic strategy to address TKI-induced diarrhea.
9.8 million people
receive chemotherapy worldwide per year
Wilson B, Jacob S, Yap M, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019;20(6):769-780. doi:10.1016/S1470-2045(19)30163-9
Chemotherapy-induced
diarrhea occurs in
50%-80%
of treated patients
Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51-63. doi:10.1177/1758834009355164
Patients with cancer therapy–
related diarrhea (CTD) were
40% more likely to
discontinue chemotherapy or
targeted cancer therapy than
patients without CTD
Okhuysen PC, Schwartzberg LS, Roeland E, et al. The impact of cancer-related diarrhea on changes in cancer therapy patterns. J Clin Oncol. 2021;39(15):12111. doi:10.1200/JCO.2021.39.15_suppl.12111
Research & Development
In October 2020, Napo Pharmaceuticals initiated a pivotal Phase 3 clinical trial
This Phase 3 study is evaluating crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy
The principal investigator and co-investigators identified are from MD Anderson Cancer Center
Jaguar Health https://jaguar.health/
Napo Pharmaceuticals https://napopharma.com/
Napo Therapeutics https://napotherapeutics.com/en/
https://www.magdalenabiosciences.com/
Magdalena is a joint venture formed by Jaguar Health and Filament Health. The company holds an exclusive license to Jaguar's proprietary library of approximately 2,300 highly characterized medicinal plants and 3,500 plant extracts for designated therapeutic indications.
Visit Jaguar on LinkedIn:
https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Phone: 415-371-8300
Contact: hello@jaguar.health
Press Releases: https://jaguarhealth.gcs-web.com/news-releases
Most if not all works by mechanism chloride ions into the gut then water comes and diarrhea out. Crofelemer normalizes abnormal ion flow targeting only locally in the gut.
Jaguar has been putting the expense into making sure Crofelemer drug supply is ready to get into this opportunity to treat cancer related chemo patients since pharmacy’s already can get FDA approved, all ready in the in the supply chain in the pharmacy as Crofelemer for AIDs patients.
Research has shown it costs 3x as much to treat a cancer patient with diarrhea.
It would be better to treat the cancer patient for diarrhea with Crofelemer pending OnTarget Study and FDA approval.
Since Crofelemer is FDA approved to treat dogs for Cancer Chemo related Diarrhea it has been said:
If your going to have cancer and cancer related Diarrhea, it’s better to be a dog than a human right now.
The companies that manufacture the cancer agents/drugs sort of point to the availability of Crofelemer because it allows them to keep their patients on their therapies thereby improving their penetration and their revenues opportunity.
3rd party market research put Short Bowel Syndrome at $5-$12 Billion opportunity because these patience are so ill, high mortality, high morbidity (the state of being unhealth for a particular disease or situation), so high of expense to manage through life.
That opportunity can be reached in small trials around the world to show benefits to be able to show global development.
Product already approved, already fully in the supply chain in the pharmacy.
Potential Market of Mytesi (crofelemer)
Jaguar and Napo $JAGX if the Phase 3 OnTarget Study has good results.
The Phase 3 OnTarget Study results are due to be out soon in this quarter.
The Phase 3 OnTarget study is testing whether the company's plant-based prescription drug crofelemer can prevent or substantially reduce diarrhea and other symptoms of CIOB when any one of the selected 24 different targeted therapies that are associated with diarrhea in patients is initiated.
Each year, more than 1 million cancer patients in the United States receive chemotherapy or radiation. Globally 9.8 million require chemotherapy.
Diarrhea is a common side effect of targeted therapies. Up to 95% of patients on tyrosine kinase inhibitors (TKIs) suffer from diarrhea, depending on the TKI used.
Any drug used to treat cancer (including tyrosine kinase inhibitors or TKIs) can be considered chemo, but here chemo is used to mean treatment with conventional cytotoxic (cell-killing) drugs that mainly kill cells that are growing and dividing rapidly. Chemo was once one of the main treatments for CML.
The cost for Mytesi oral delayed release tablet 125 mg is around $2,600 for a supply of 60 tablets. This amount is the one month supply as testing in the OnTarget Study.
That is a 24 week study = 5.6 month supply needed = $14,560.00 for treatment.
Potential Market of Mytesi (crofelemer)
100,000 patients a year = $1,456,000,000
250,000 patients a year = $3,640,000,000
500,000 patients a year = $7,280,000,000
1,000,000 patients a year = $14,560,000,000 (assuming worldwide)
5,000,000 patients a year = $72,800,000,000 (assuming worldwide)
The estimate of patients depends on how many quit taking chemo, the onTarget Study, FDA approval and or quit taking Mytesi (crofelemer).
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |